“How to” guide for pharmacist‐led implementation of beta‐lactam therapeutic drug monitoring in the critically ill
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2023-08 · 6 (8) · 964-975
DOI: 10.1002/jac5.1819 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, online erschienen am 08.06.2023. Verfasst von Sara E Ausman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic Health System, Eau Claire, Wisconsin, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Beta‐lactam therapeutic drug monitoring (TDM) can improve precision dosing and clinical outcomes in critically ill patients, but has not been implemented widely in the United States. Mayo Clinic recently implemented a beta‐lactam TDM program. This single‐center experience forms the basis of the manuscript which outlines practical considerations involved with beta‐lactam TDM implementation, including the pharmacist's role as a leader. Our implementation effort focused on three primary domains. First, we aimed to ensure a supportive organizational infrastructure. Early leadership engagement by the pharmacist‐led core team facilitated advocacy for the clinical need, allocation of resources, and assay development. Second, core clinical workflows were developed that addressed the preferred patient population for use, desirable pharmacokinetic and pharmacodynamic targets, and the preferred sampling strategy. Clinical tools to guide pharmacists in interpreting the results (e.g., pharmacokinetics calculator) and documenting decisions were developed. Third, stakeholders were offered repeated exposure to evidence and expertise to facilitate understanding and application of the new practice. This act of ‘individual internalization’ seems to be uniquely important to beta‐lactam TDM implementation compared with the implementation of other antimicrobial TDM programs. Educational strategies and supportive materials that were developed were focused on providing substantive and varied information tailored to the stakeholders' role in the process. For pharmacists, this included both clinical and operational considerations. A continuous improvement plan to support management of the process was instituted to address necessary updates and changes that inevitably emerged. In summary, the described approach to implementation of a pharmacist‐led beta‐lactam TDM program could be used as a roadmap to aid other institutions that aim to develop such a program.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic Health System, Eau Claire, Wisconsin, USA.
- Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Strategy Department, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Sara E Ausman, Lindsay N Moreland-Head, Paul J Jannetto, Christina G Rivera, Rebecca J Wessel, Patrick M Wieruszewski, Erin F Barreto
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Ausman, S. E., Moreland-Head, L. N., Abu Saleh, O. M., Jannetto, P. J., Rivera, C. G., Stevens, R. W., Wessel, R. J., Wieruszewski, P. M., Barreto, E. F., & BLOOM Study group (2023). “How to” guide for pharmacist‐led implementation of beta‐lactam therapeutic drug monitoring in the critically ill. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 6(8), 964-975. https://doi.org/10.1002/jac5.1819
Vancouver
Ausman SE, Moreland-Head LN, Abu Saleh OM, Jannetto PJ, Rivera CG, Stevens RW, et al. “How to” guide for pharmacist‐led implementation of beta‐lactam therapeutic drug monitoring in the critically ill. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2023;6(8):964-975. doi:10.1002/jac5.1819
BibTeX
@article{Ausman2023,
author = {Ausman, Sara E and Moreland-Head, Lindsay N and Abu Saleh, Omar M and Jannetto, Paul J and Rivera, Christina G and Stevens, Ryan W and Wessel, Rebecca J and Wieruszewski, Patrick M and Barreto, Erin F and BLOOM Study group, BLOOM Study group},
title = {“How to” guide for pharmacist‐led implementation of beta‐lactam therapeutic drug monitoring in the critically ill},
journal = {JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY},
year = {2023},
volume = {6},
number = {8},
pages = {964--975},
doi = {10.1002/jac5.1819}
}
EUVIMED